Enveric Biosciences short interest was 45.7% of the float on April 30th, according to new data we received from Benzinga. Short interest totaled 886,509 shares, which was an increase of 1,306.64% from April 15th.
It is estimated that it would take 1.0 days for short sellers to buy back their shares, with current trading volumes.
Enveric Biosciences Hedge Fund Activity
We have seen 10 institutional investors add shares of Enveric Biosciences stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GEODE CAPITAL MANAGEMENT, LLC removed 2,375 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $8,621
- CITIGROUP INC added 2,276 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,261
- CITADEL ADVISORS LLC removed 1,889 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $6,857
- TOWER RESEARCH CAPITAL LLC (TRC) added 1,716 shares (+853.7%) to their portfolio in Q4 2025, for an estimated $6,229
- UBS GROUP AG added 717 shares (+24.8%) to their portfolio in Q1 2026, for an estimated $1,390
- SBI SECURITIES CO., LTD. added 34 shares (+69.4%) to their portfolio in Q1 2026, for an estimated $65
- BANK OF AMERICA CORP /DE/ added 3 shares (+150.0%) to their portfolio in Q4 2025, for an estimated $10
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
